A federal review board voted Thursday to loosen rules on seven peptides, including BPC-157 and TB-500. The vote was narrow. It is advisory only. The FDA has given no signal on whether it will move in step with the panel. The move came after weeks of public comment sessions. Wellness backers pressed strongly for wider access. RFK Jr. was among them. Critics say these compounds have insufficient safety data or help for most uses. The call could change how the agency handles a part of the wellness market that is scaling quickly. Industry players are waiting to see if the regulator moves in step. A spokesperson for the regulator offered no firm timeline for a response. Critics argue the change would grant more access to products users find useful. Health groups warn that looser rules could invite misuse across a quickly growing market. The vote only sets up a possible shift, and the final decision rests with the federal agency.